{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:33:19Z","timestamp":1767339199885,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.11.027","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T05:57:22Z","timestamp":1543298242000},"page":"397-399","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol"],"prefix":"10.1016","volume":"27","author":[{"given":"William L","family":"Conte","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Arndt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica P","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Dellaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.11.027_bib0001","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10522-009-9256-9","article-title":"The ageing B cell population: composition and function","volume":"11","author":"Ademokun","year":"2010","journal-title":"Biogerontology"},{"key":"10.1016\/j.msard.2018.11.027_bib0002","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/ni.3215","article-title":"Inflammation-induced formation of fat-associated lymphoid clusters","volume":"16","author":"B\u00e9n\u00e9zech","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.msard.2018.11.027_bib0003","doi-asserted-by":"crossref","first-page":"B304","DOI":"10.1093\/gerona\/57.8.B304","article-title":"Altered memory B-cell homeostasis in human aging","volume":"57","author":"Breitbart","year":"2002","journal-title":"J. Gerontol. A. Biol. Sci. Med. Sci."},{"key":"10.1016\/j.msard.2018.11.027_bib0004","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7224\/1537-2073.2014-030","article-title":"Prevention and management of infusion-associated reactions in the comparison of alemtuzumab and rebif \u00ae efficacy in multiple sclerosis (CARE-MS) program","volume":"17","author":"Caon","year":"2015","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2018.11.027_bib0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/intimm\/dxh218","article-title":"CD27(+) (memory) B cell decrease and apoptosis-resistant CD27(-) (naive) B cell increase in aged humans: implications for age-related peripheral B cell developmental disturbances","volume":"17","author":"Chong","year":"2005","journal-title":"Int. Immunol."},{"key":"10.1016\/j.msard.2018.11.027_bib0006","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.4049\/jimmunol.180.8.5283","article-title":"Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells","volume":"180","author":"Frasca","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2018.11.027_bib0007","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11910-017-0771-9","article-title":"Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2018.11.027_bib0008","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1172\/JCI0214873","article-title":"Estrogen alters thresholds for B cell apoptosis and activation","volume":"109","author":"Grimaldi","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2018.11.027_bib0009","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.027_bib0010","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.11.027_bib0011","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.4049\/jimmunol.152.8.3760","article-title":"Adhesion through the LFA-1 (CD11a\/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells","volume":"152","author":"Koopman","year":"1994","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2018.11.027_bib0012","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood.V89.3.853","article-title":"Role of bcl-2 in the development of lymphoid cells from the hematopoietic stem cell","volume":"89","author":"Matsuzaki","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.msard.2018.11.027_bib0013","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.027_bib0014","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2018.11.027_bib0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1365-2249.1992.tb07954.x","article-title":"Changes in circulating B cells and immunoglobulin classes and subclasses in a healthy aged population","volume":"90","author":"Paganelli","year":"1992","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.msard.2018.11.027_bib0016","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12026-013-8444-5","article-title":"Impaired B lymphopoiesis in old age: a role for inflammatory B cells?","volume":"57","author":"Riley","year":"2013","journal-title":"Immunol. Res."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818305200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:16Z","timestamp":1761900196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818305200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":16,"alternative-id":["S2211034818305200"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.027","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}